CCM
BSX icon

Cadian Capital Management’s Boston Scientific BSX Stock Holding History

Cadian Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.2M Buy
1,105,132
+935,132
+550% +$50.8M 3.57% 13
2026
Q1 		$10.7M Buy
+170,000
New +$13.6M 1.3% 19

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cadian Capital Management's BSX Position: Q2 2026 in Review

Cadian Capital Management increased its Boston Scientific (BSX) stake by 550% in Q2 2026, buying an estimated $50.8M and bringing the position to 1,105,132 shares worth $47.2M. The position accounts for 3.57% of the portfolio, ranked #13.

Cadian Capital Management first reported a position in BSX in Q1 2026 and has held it in 2 quarters since. 1,474 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Cadian Capital Management held 1,105,132 shares of Boston Scientific worth $47.2M as of Q2 2026.
  • Cadian Capital Management bought 935,132 Boston Scientific shares in Q2 2026, an estimated $50.8M.
  • Boston Scientific made up 3.57% of Cadian Capital Management's portfolio in Q2 2026, its #13 holding.
  • Cadian Capital Management first reported a position in Boston Scientific in Q1 2026 and has held it in 2 quarters since.
  • 1,474 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Cadian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.